[Successfully second line treatment with selinexor-bortezomib-dexamethasone of a patient affected by multiple myeloma, refractory to first line therapy with daratumab-lenalidomide-dexamethasone] [0.03%]
一位接受达雷妥尤单抗-来那度胺-地塞米松一线治疗后复发的多发性骨髓瘤患者成功采用_selinexor-硼替佐米-地塞米松二线治疗案例报告
Laura Paris
Laura Paris
Refractoriness to first-line therapy with daratumumab and lenalidomide represents the paradigm of patients with functional high-risk multiple myeloma. In Italy, the currently available second-line therapies have been approved based on phase...
[Early use of selinexor-bortezomib-dexamethasone after anti-CD38-based therapy in multiple myeloma: a case report] [0.03%]
塞利尤索夫-硼替佐米-地塞米松治疗基于抗CD38疗法的多发性骨髓瘤的早期应用：病例报告
Antonia Cagnetta,Matteo Garibotto
Antonia Cagnetta
In transplant-ineligible patients with multiple myeloma (MM), disease relapse represents a critical step in the therapeutic pathway. The increasingly early use of frontline regimens containing anti-CD38 monoclonal antibodies has led to sign...
[Deep and durable response with the selinexor-bortezomib-dexamethasone combination in a patient with multiple myeloma refractory to first-line treatment] [0.03%]
塞利尼索-硼替佐米地塞米松联合方案治疗初治复发难治多发性骨髓瘤患者的深度有效反应案例报告
Roberta Della Pepa
Roberta Della Pepa
The management of relapsed or refractory multiple myeloma in elderly patients remains challenging, particularly in cases of early refractoriness to first-line anti-CD38-based regimens, which is associated with poor prognosis and limited the...
Maria Chiara Tisi,Michele Wieczorek,Marcello Riva
Maria Chiara Tisi
Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), setting as the new standard of care. Below, we describe the case history of a 69-year-old fema...
[CAR-T cell therapy in an elderly patient with DLBCL and early relapse ( [0.03%]
老年DLBCL早期复发患者进行CAR-T细胞治疗
Enrico Orciuolo
Enrico Orciuolo
We report a successful therapeutic case of axi-cell therapy in an elderly patient diagnosed with diffuse large B-cell lymphoma (DLBCL), experiencing early relapse after first-line treatment. The complications that arose during hospitalizati...
[Refractory DLBCL to a polatuzumab-containing regimen: efficacy of CAR-T therapy in second line with radiotherapy bridging] [0.03%]
[对ポラツズマブ含む化学療法抵抗性DLBCL患者のCAR-T治療第2線導入時の効果と化学放射線橋接療法の有用性]
Guido Gini,Francesco Saraceni
Guido Gini
DLBCL represents the prototype of aggressive lymphomas; despite therapeutic advances, a substantial proportion of patients remain refractory to first-line treatment. Anti-CD19 CAR-T therapy has revolutionized the second-line setting for pat...
[Beyond comorbidities: CAR-T as a safe and effective option in frail patients with second-line DLBCL] [0.03%]
[超越合并症：CAR-T作为二线DLBCL虚弱患者的高效安全选择]
Eugenio Galli
Eugenio Galli
CD19 CAR-T therapy is the second-line standard for relapsed/refractory DLBCL, yet the management of frail patients remains debated due to toxicity and non-relapse mortality risks. We report a 74-year-old man with high-risk DLBCL and multipl...
[CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy] [0.03%]
初程化疗免疫治疗后早期复发的CAR-T细胞免疫治疗
Livia Donzelli,Alice Di Rocco
Livia Donzelli
CAR-T therapies represent a major advance in the management of large B-cell lymphomas. Axi-cel, the only product approved in Italy as a second-line treatment, demonstrated superiority over standard therapy in the randomized phase 3 ZUMA-7 t...
[Efficacy of axi-cel in a patient with high-grade large B-cell lymphoma refractory to first-line therapy: importance of early identification and referral of the patient potentially eligible for CAR-T in defining the patient's outcome] [0.03%]
[Axi-cel治疗一线治疗无效的高大B细胞淋巴瘤患者的疗效：早期识别和转诊潜在CAR-T候选患者对预后的影响]
Beatrice Casadei,Pier Luigi Zinzani
Beatrice Casadei
CAR-T cell therapy has revolutionized second-line treatment for patients with refractory/relapsed large B-cell lymphoma within 12 months, demonstrating clear superiority in terms of both response rate and survival compared to salvage chemot...